Takuma Isshiki1, Hisayo Matsuyama2, Tetsuo Yamaguchi3, Toshisuke Morita4, Junya Ono5, Satoshi Nunomura6, Kenji Izuhara7, Susumu Sakamoto8, Sakae Homma9, Kazuma Kishi10. 1. Department of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan. Electronic address: takuma.isshiki@med.toho-u.ac.jp. 2. Department of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan. Electronic address: hisayo-matsuyama@hotmail.co.jp. 3. Shinjuku Tsurukame Clinic, Tokyo, Japan. Electronic address: yamatet@icloud.com. 4. Department of Laboratory Medicine, Toho University School of Medicine, Tokyo, Japan. Electronic address: toshimrt@med.toho-u.ac.jp. 5. Shino-test Co. Ltd, Tokyo, Japan. Electronic address: junya.ono@shino-test.co.jp. 6. Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan. Electronic address: nunomura@cc.saga-u.ac.jp. 7. Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan. Electronic address: kizuhara@cc.saga-u.ac.jp. 8. Department of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan. Electronic address: susumu1029@med.toho-u.ac.jp. 9. Department of Advanced and Integrated Interstitial Lung Disease Research, School of Medicine, Toho University, Tokyo, Japan. Electronic address: sahomma@med.toho-u.ac.jp. 10. Department of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan. Electronic address: kazuma.kishi@med.toho-u.ac.jp.
Abstract
BACKGROUND: Some patients with sarcoidosis experience worsening of pulmonary lesions. However, no biomarker has been identified that reflects pulmonary disease status in sarcoidosis. We investigated the usefulness of potential markers of pulmonary fibrosis in patients with sarcoidosis. METHODS: Plasma matrix metalloproteinase 7 (MMP-7), CC-chemokine ligand 18 (CCL-18), and periostin levels were evaluated in 60 patients with sarcoidosis and 30 healthy controls; bronchoalveolar lavage fluid levels were analyzed in 22 patients with sarcoidosis. To determine the usefulness of these markers, we explored potential correlations between these markers and sarcoidosis clinical characteristics. RESULTS: Plasma MMP-7, CCL-18, and periostin concentrations were significantly higher in patients with sarcoidosis than those in healthy controls. MMP-7 concentrations in plasma and bronchoalveolar lavage fluid were higher in patients with sarcoidosis with parenchymal infiltration than in those without lung lesions. Moreover, MMP-7 concentration was negatively correlated with pulmonary function. CONCLUSION: Among these novel biomarkers, MMP-7 most precisely reflected pulmonary sarcoidosis disease status and thus, might be useful for diagnosing and evaluating sarcoidosis, particularly in patients with pulmonary parenchymal lesions.
BACKGROUND: Some patients with sarcoidosis experience worsening of pulmonary lesions. However, no biomarker has been identified that reflects pulmonary disease status in sarcoidosis. We investigated the usefulness of potential markers of pulmonary fibrosis in patients with sarcoidosis. METHODS: Plasma matrix metalloproteinase 7 (MMP-7), CC-chemokine ligand 18 (CCL-18), and periostin levels were evaluated in 60 patients with sarcoidosis and 30 healthy controls; bronchoalveolar lavage fluid levels were analyzed in 22 patients with sarcoidosis. To determine the usefulness of these markers, we explored potential correlations between these markers and sarcoidosis clinical characteristics. RESULTS: Plasma MMP-7, CCL-18, and periostin concentrations were significantly higher in patients with sarcoidosis than those in healthy controls. MMP-7 concentrations in plasma and bronchoalveolar lavage fluid were higher in patients with sarcoidosis with parenchymal infiltration than in those without lung lesions. Moreover, MMP-7 concentration was negatively correlated with pulmonary function. CONCLUSION: Among these novel biomarkers, MMP-7 most precisely reflected pulmonary sarcoidosis disease status and thus, might be useful for diagnosing and evaluating sarcoidosis, particularly in patients with pulmonary parenchymal lesions.
Authors: Jan C Kamp; Lavinia Neubert; Helge Stark; Jan B Hinrichs; Caja Boekhoff; Allison D Seidel; Fabio Ius; Axel Haverich; Jens Gottlieb; Tobias Welte; Peter Braubach; Florian Laenger; Marius M Hoeper; Mark P Kuehnel; Danny D Jonigk Journal: Cells Date: 2022-02-14 Impact factor: 6.600